




Mouse Anti-Human IgG₄ Fc

Cat. No.	Format	Size
9200-01	Purified (UNLB)	0.5 mg
9200-02	Fluorescein (FITC)	0.5 mg
9200-04	Alkaline Phosphatase (AP)	1.0 mL
9200-05	Horseradish Peroxidase (HRP)	1.0 mL
9200-08	Biotin (BIOT)	0.5 mg
9200-09	R-phycoerythrin (PE)	0.1 mg
9200-30	Alexa Fluor [®] 488 (AF488)	0.1 mg
9200-31	Alexa Fluor [®] 647 (AF647)	0.1 mg
9200-32	Alexa Fluor [®] 555 (AF555)	0.1 mg



FLISA plate was coated with purified human IgG1, IgG2, IgG3, and IgG4. Immunoglobulins were detected with serially diluted Mouse Anti-Human IgG4 Fc-PE (SB Cat. No. 9200-09).

Overview

Clone	HP6025
Isotype	Mouse (BALB/c) IgG ₁ κ
Immunogen	Human IgG ₄ myeloma protein
Specificity	Human IgG ₄ Fc; Mr 146 kDa

Applications

ELISA – Quality tested²⁻⁹
 FLISA – Quality tested
 FC – Reported in literature^{15,18,19}
 IHC-FS – Reported in literature¹⁰
 IHC-PS – Reported in literature^{5,7,10,11}
 ICC – Reported in literature¹²
 WB – Reported in literature^{3,13-16}
 Microarray – Reported in literature¹⁷
 Multiplex – Reported in literature^{2,20-22}
 Purification – Reported in literature¹⁵

Working Dilutions

ELISA	AP conjugate	1:1,000 – 1:2,000
	HRP conjugate	1:4,000 – 1:8,000
	BIOT conjugate	1:5,000 – 1:10,000
FLISA	FITC, AF488, and AF555 conjugates	1:200 – 1:400
	PE and AF647 conjugates	≤ 1 µg/mL

Other Applications Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL of stock solution in 50 mM Tris/1 mM MgCl₂/50% glycerol, pH 8.0, containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL of stock solution in 50% glycerol/50% PBS, pH 7.4. No preservative added. Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Alexa Fluor[®] 488 (AF488), Alexa Fluor[®] 555 (AF555), and Alexa Fluor[®] 647 (AF647) conjugates are supplied as 0.1 mg in 0.2 mL of PBS/NaN₃. Store at 2-8°C.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific (M)SDS.

References

1. Reimer CB, Phillips DJ, Aloisio CH, Moore DD, Galland GG, Wells TW, et al. Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. *Hybridoma*. 1984;3:263-75. (Immunogen)
2. Arnold M, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in transplant candidates. *Tissue Antigens*. 2008;72:60-6. (ELISA, Multiplex)
3. Bogdanos D, Pustl T, Rust C, Vergani D, Beuers U. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. *J Hepatol*. 2008;49:466-73. (ELISA, WB)
4. Forthall DN, Landucci G, Ding H, Kappes JC, Wang A, Thung I, et al. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. *AIDS*. 2011;25:2099-104. (ELISA)
5. Jia X, Hu S, Chen J, Qu Z, Liu G, Cui Z, et al. The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy. *Kidney Int*. 2014;85:945-52. (ELISA, IHC-PS)
6. Xu J, Wang L, Deng C, Hu X, Li R, Chen T, et al. The serological diagnosis of human clonorchiasis by time-resolved fluoroimmunoassay based on GST2-specific IgG4 detection. *Parasitol Res*. 2014;113:149-55. (ELISA)
7. Zhang J, Zhao L, Gao Y, Liu M, Li T, Huang Y, et al. A classification of Hashimoto's thyroiditis based on immunohistochemistry for IgG4 and IgG. *Thyroid*. 2014;24:364-70. (ELISA, IHC-PS)
8. Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. *Clin Exp Immunol*. 2014;178:40-7. (ELISA)
9. Seitz-Polski B, Payré C, Ambrosetti D, Albano L, Cassuto-Viguier E, Berguignat M, et al. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. *Nephrol Dial Transplant*. 2014;29:2334-42. (ELISA)
10. Detlefsen S, Bräsen JH, Zamboni G, Capelli P, Klöppel G. Deposition of complement C3c, immunoglobulin (Ig)G4 and IgG at the basement membrane of pancreatic ducts and acini in autoimmune pancreatitis. *Histopathology*. 2010;57:825-35. (IHC-FS, IHC-PS)
11. Qu Z, Liu G, Li J, Wu L, Tan Y, Zheng X, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. *Nephrol Dial Transplant*. 2012;27:1931-7. (IHC-PS)
12. de Bruin A, Caldelari R, Williamson L, Suter MM, Hunziker T, Wyder M, et al. Plakoglobin-dependent disruption of the desmosomal plaque in pemphigus vulgaris. *Exp Dermatol*. 2007;16:468-75. (ICC)
13. Müller E, Kernland K, Caldelari R, Wyder M, Balmer V, Hunziker T, et al. Unusual pemphigus phenotype in the presence of a Dsg1 and Dsg3 autoantibody profile. *J Invest Dermatol*. 2002;118:551-5. (WB)
14. Bogdanos D, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. *J Autoimmun*. 2004;22:353-62. (WB)
15. Keen J, Serghides L, Ayi K, Patel SN, Ayisi J, van Eijk A, et al. HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. *PLoS Med*. 2007;4(5):e181. (WB, FC, Purification)
16. Parcina M, Miranda-Garcia MA, Durlanik S, Ziegler S, Over B, Georg P, et al. Pathogen-triggered activation of plasmacytoid dendritic cells induces IL-10-producing B cells in response to Staphylococcus aureus. *J Immunol*. 2013;190:1591-602. (WB)
17. Savilahti EM, Rantanen V, Lin JS, Karinen S, Saarinen KM, Goldis M, et al. Early recovery from cow's milk allergy is associated with decreasing IgE and increasing IgG4 binding to cow's milk epitopes. *J Allergy Clin Immunol*. 2010;125:1315-21. (Microarray)
18. Johansson SE, Hejdeman B, Hinkula J, Johansson MH, Romagné F, Wahren B, et al. NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients. *Clin Immunol*. 2010;134:158-68. (FC)
19. Gao B, Moore C, Porcheray F, Rong C, Abidoglu C, DeVito J, et al. Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. *Am J Transplant*. 2014;14:1581-91. (FC)
20. Lowe D, Higgins R, Zehnder D, Briggs DC. Significant IgG subclass heterogeneity in HLA-specific antibodies: Implications for pathogenicity, prognosis, and the rejection response. *Hum Immunol*. 2013;74:666-72. (Multiplex)
21. Arnold M, Ntokou I, Doxiadis II, Spriewald BM, Boletis JN, Iniotaki AG. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. *Transpl Int*. 2014;27:253-61. (Multiplex)
22. Schaub S, Hönger G, Koller MT, Liwski R, Amico P. Determinants of C1q binding in the single antigen bead assay. *Transplantation*. 2014;98:387-93. (Multiplex)

Alexa Fluor[®] 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.

TB9200

18-Nov-16

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com